Trial Profile
Randomized, Double-Blind, Placebo-Controlled, Multiple Dose, Dose-Escalation Study of STX-100 in Patients With Idiopathic Pulmonary Fibrosis (IPF)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Oct 2021
Price :
$35
*
At a glance
- Drugs BG 00011 (Primary)
- Indications Idiopathic pulmonary fibrosis
- Focus Adverse reactions
- Sponsors Biogen
- 19 Sep 2018 Results presented at the 28th Annual Congress of the European Respiratory Society
- 23 May 2018 Results presented at the 114th International Conference of the American Thoracic Society
- 18 May 2017 Status changed from active, no longer recruiting to completed.